Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products-Reference-Cited by-同舟云学术

Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products

Published:2018-05-30 Issue:7 Volume:84 Page:1401-1409
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

van Gerven Joop¹^ORCID,Bonelli Milton²^ORCID

Affiliation:

1. Central Committee on Research Involving Human Subjects CCMO; The Hague The Netherlands

2. Human Medicines Research and Development Support Division; European Medicines Agency; London UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13550/fullpdf

Reference32 articles.

1. European Medicines Agency Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products (EMEA/CHMP/SWP/28367/07 Rev. 1) 2017

2. Analysis of integrated clinical trial protocols in early phases of medicinal product development;Fruhner;Eur J Clin Pharmacol,2017

3. Expert group on phase one clinical trials (chairman: Professor Gordon W. Duff) expert group on phase one clinical trials: final report 2006 TSO (the stationary office)

4. The TeGenero incident and the Duff Report conclusions: a series of unfortunate events or an avoidable event?;Horvath;Toxicol Pathol,2009

5. Establishing risk of human experimentation with drugs: lessons from TGN1412;Kenter;Lancet,2006

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS‐CoV‐2;British Journal of Clinical Pharmacology;2023-11-22

2. Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study;BMC Medicine;2023-07-05

3. Safety, Tolerability and Pharmacokinetics of Single-Dose Oral SYHA1402 in Healthy Chinese Subjects;Neurology and Therapy;2023-04-24

4. Trends of Phase I Clinical Trials in the Latest Ten Years across Five European Countries;International Journal of Environmental Research and Public Health;2022-10-28

5. Preclinical efficacy in investigator's brochures: Stakeholders' views on measures to improve completeness and robustness;British Journal of Clinical Pharmacology;2022-08-31